Suppr超能文献

原发性小肠弥漫性大B细胞淋巴瘤的临床特征分析及生存列线图

Clinical Features Analysis and Survival Nomogram of Primary Small Intestinal Diffuse Large B-Cell Lymphoma.

作者信息

Liu Xiaohong, Cao Dedong, Liu Hui, Ke Dong, Ke Xiaokang, Xu Ximing

机构信息

Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, 430060, People's Republic of China.

Department of Hematology, Renmin Hospital of Wuhan University, Wuhan, 430060, People's Republic of China.

出版信息

Cancer Manag Res. 2022 Sep 5;14:2639-2648. doi: 10.2147/CMAR.S369086. eCollection 2022.

Abstract

PURPOSE

This study aimed to analyze the clinical features and survival of primary small intestinal diffuse large B-cell lymphoma (PsI-DLBCL), and establish and independently validate a prognostic nomogram for individual risk prediction.

PATIENTS AND METHODS

Data for 24 patients from the Renmin Hospital of Wuhan University were used as an independent validation cohort, data for 1144 patients with PsI-DLBCL from the SEER database were randomly assigned to training (N=817) and internal validation (N=327) sets. The survival nomogram was constructed with the most significant factors associated with OS using Univariate and multivariate analyses on the training set. Decision curve analysis (DCA) was conducted. Internal validation was SEER validation set. Our cancer center cohort was used as an external validation set to further verify the survival nomogram.

RESULTS

Five clinicopathological feature factors associated with OS of the training set yielded (age, marital status, Ann Arbor stage, surgery for primary site and chemotherapy), which were used to create a survival nomogram. Additionally, the calibration curves of the prognostic nomogram revealed good agreement between the predicted survival probabilities and the ground truth values. The stability of our survival nomogram was explained by internal and external validation data.

CONCLUSION

Our nomogram proposes the clinical and therapeutic factors affecting OS for patients with PsI-DLBCL. It shows that chemotherapy and surgery are beneficial to patients in the choice of treatment options. These results suggest that a survival nomogram may be better at predicting OS for PsI-DLBCL patients.

摘要

目的

本研究旨在分析原发性小肠弥漫性大B细胞淋巴瘤(PsI-DLBCL)的临床特征和生存情况,并建立和独立验证用于个体风险预测的预后列线图。

患者与方法

将武汉大学人民医院24例患者的数据用作独立验证队列,将来自监测、流行病学与最终结果(SEER)数据库的1144例PsI-DLBCL患者的数据随机分配至训练集(N = 817)和内部验证集(N = 327)。使用训练集进行单因素和多因素分析,以与总生存期(OS)相关的最显著因素构建生存列线图。进行决策曲线分析(DCA)。内部验证采用SEER验证集。将我们癌症中心的队列用作外部验证集,以进一步验证生存列线图。

结果

训练集的5个与OS相关的临床病理特征因素(年龄、婚姻状况、Ann Arbor分期、原发部位手术和化疗)被用于创建生存列线图。此外,预后列线图的校准曲线显示预测生存概率与实际观察值之间具有良好的一致性。内部和外部验证数据说明了我们生存列线图的稳定性。

结论

我们的列线图提出了影响PsI-DLBCL患者OS的临床和治疗因素。结果表明,在治疗方案选择中,化疗和手术对患者有益。这些结果提示,生存列线图可能能更好地预测PsI-DLBCL患者的OS。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60b3/9462437/81fa707e22d0/CMAR-14-2639-g0001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验